Cited 26 times in
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 임종근 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-05-19T17:25:51Z | - |
dc.date.available | 2015-05-19T17:25:51Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/108133 | - |
dc.description.abstract | BACKGROUND: This phase II study describes the efficacy and safety of combination chemotherapy of 5-fluorouracil (5-FU), low-dose leucovorin, and oxaliplatin (FLOX regimen) for pretreated advanced gastric cancer. PATIENTS AND METHODS: Patients who had been previously treated with greater than or equal to one regimen were enrolled. Patients received an oxaliplatin 75 mg/m(2) on day 1, 5-FU 1000 mg/m(2) on days 1-3, and leucovorin 20 mg/m(2) on days 1-3, every 3 weeks. The primary end point was overall survival (OS). RESULTS: Among the 52 patients enrolled, 26 patients were treated as second line, and the remaining 26 patients were enrolled as third- or fourth line. A total of 203 cycles of chemotherapy were administered with the median being three cycles (range 1-15) per patient. The median OS was 6.6 months [95% confidence interval (CI) 4.5-8.8] and the median progression-free survival was 2.5 months (95% CI 1.9-3.0). The response rate was 4% (95% CI 0-9%), and the disease control rate was 48% (95% CI 34-62%). The most common toxic effects of grade 3/4 were neutropenia (16%) and vomiting (6%). CONCLUSIONS: The FLOX regimen showed modest activity as a salvage treatment in pretreated advanced gastric cancer with a favorable compliance. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1135~1140 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Oxaliplatin | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/mortality | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.title | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | J. Jeong | - |
dc.contributor.googleauthor | H.-C. Jeung | - |
dc.contributor.googleauthor | S. Y. Rha | - |
dc.contributor.googleauthor | C. K. Im | - |
dc.contributor.googleauthor | S. J. Shin | - |
dc.contributor.googleauthor | J. B. Ahn | - |
dc.contributor.googleauthor | S. H. Noh | - |
dc.contributor.googleauthor | J. K. Roh | - |
dc.contributor.googleauthor | H. C. Chung | - |
dc.identifier.doi | 10.1093/annonc/mdn013 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A03402 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.pmid | 18272910 | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Fluorouracil/administration & dosage | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Leucovorin/administration & dosage | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Organoplatinum Compounds/administration & dosage | - |
dc.subject.keyword | Oxaliplatin | - |
dc.subject.keyword | Salvage Therapy | - |
dc.subject.keyword | Stomach Neoplasms/drug therapy* | - |
dc.subject.keyword | Stomach Neoplasms/mortality | - |
dc.subject.keyword | Stomach Neoplasms/pathology | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Im, Chong Kun | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Im, Chong Kun | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 19 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1135 | - |
dc.citation.endPage | 1140 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.19(6) : 1135-1140, 2008 | - |
dc.identifier.rimsid | 35206 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.